As a result of this growing body of evidence that TSPAN5 may play a role in both MDD and AUD risk, the present study was designed to explore the biological function of TSPAN5 with a focus on the tryptophan pathway using human iPSC-derived CNS cells exposed to either ethanol (EtOH) or acamprosate—an FDA approved medication for the treatment of AUD [7]. This evidence concerns the gene TSPAN5 and major depressive disorder.